Tubulis, based in Munich, is developing antibody-drug conjugates, which are next-generation chemotherapies.
Today's biotech news includes how thin science fuels peptide hype, blowback to proposed NIH cuts, and a stealth biotech's secret ADCs
By the time FDA agreed to meet with Kezar Life Sciences it was in the process of closing. The chain of events fits a pattern of FDA volatility recently.
Trump's White House is embracing ideas to bring more pharmaceutical manufacturing to the U.S.
